SlideShare a Scribd company logo
1 of 42
Analysis and Interpretation: Overview ,[object Object],[object Object],[object Object],[object Object],[object Object]
Framework for synthesis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Why Perform a Meta-analysis? ,[object Object],[object Object],[object Object],[object Object],[object Object]
More on Meta-analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]
When not Appropriate to do M/a ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dichotomous Measures ,[object Object],[object Object],[object Object],[object Object]
Risk ratio (RR)  aka relative risk RR =   a / (a+b)  c / (c+d) Risk/ probability/ chance  of the occurrence of an event in treatment relative to control Intervention Control a+b=n I c+d=n C Event No event d c b a
Sample RR Calculation Death No death RR =   14/133  =  0.11  = 0.13 128/148  0.86 Drug 133 148 Placebo 20 128 119 14
Odds ratio (OR) Intervention Control No event Event OR =  a / b  c / d  Odds of an event occurring to it not occurring for treatment relative to control a+b=n I c+d=n C d c b a
Sample OR Calculation Death No death Drug Placebo 133 148 OR =   14/119  =  0.12  = 0.019 128/20  6.4 20 128 119 14
Interpreting (for intervention) Increased odds (harmful) Increased odds  (beneficial) OR>1 (6.4/0.12) Reduced odds (beneficial) Reduced odds (not beneficial) OR<1 (0.12/6.4) No difference No difference OR=1, RR=1 Increased risk (harmful) Increased risk  (beneficial) RR>1 (0.86/0.11) Reduced risk  (beneficial) Reduced risk (not beneficial) RR<1 (0.11/0.86) Bad outcome  (e.g. infection) Good outcome (e.g. remission)
RR vs. OR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Closer Look at Odds RR = 0.11 / 0.86 = 0.13 ↑ A rate (11%) OR = 0.12 / 6.4  = 0.019 ↑ ~1:9 ↑ ~7:1
Absolute Effect Measures ,[object Object],[object Object]
Risk Difference (RD) Death No death Actual difference in  risk of events Placebo Drug 133 148 RD = 14/133 – 128/148 = 0.11 – 0.86 = - 0.75 20 128 119 14
Risk Difference (RD)  (continued) ,[object Object],[object Object],[object Object]
NNT ,[object Object],[object Object],[object Object],[object Object],[object Object]
Uncertainty ,[object Object],[object Object],[object Object],[object Object]
Which effect measure for meta-analysis? ,[object Object],[object Object],[object Object]
Meta-analysis in RevMan
Meta-analysis in RevMan  (continued) ,[object Object],[object Object]
Fixed vs Random Effects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fixed Effects Analysis in Picture View
Random Effects Analysis in Picture View
Random effects in RevMan 5 ←  DerSimonian and Laird  random effects model
Random effects in RevMan 5  (continued) ←  DerSimonian and Laird  random effects model
Sample Forest plot (RR) ,[object Object]
Meta-analysis for Continuous Data ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Mean Difference (MD) ,[object Object],[object Object]
Standardized Mean Difference (SMD) ,[object Object]
Heterogeneity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
    Clinical and Methodologic Heterogeneity  ,[object Object],[object Object],[object Object]
Statistical Heterogeneity ,[object Object],[object Object]
Q test ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I 2  Statistic ,[object Object],[object Object],[object Object]
I 2  Statistic  (continued) * Importance of I 2  value depends on: ●  magnitude and direction of effects ●  strength of evidence of heterogeneity - Chi-squared P value, or - I 2  confidence interval Considerable heterogeneity*  75% to 100% May represent substantial heterogeneity* 50% to 90% May represent moderate heterogeneity* 30% to 60% Might not be important 0% to 40% Guide to Interpretation I 2  value
Sample Forest Plot:  Q and I 2
What to do with (Statistical) Heterogeneity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What to do with (Statistical) Heterogeneity ,[object Object],[object Object],[object Object],[object Object]
Subgroup and Meta-regression ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Subgroup Analysis
Sensitivity Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

bio statistics for clinical research
bio statistics for clinical researchbio statistics for clinical research
bio statistics for clinical researchRanjith Paravannoor
 
Question study design
Question study designQuestion study design
Question study designAnisur Rahman
 
Inferential statictis ready go
Inferential statictis ready goInferential statictis ready go
Inferential statictis ready goMmedsc Hahm
 
Parametric Survival Analysis in Health Economics
Parametric Survival Analysis   in Health Economics Parametric Survival Analysis   in Health Economics
Parametric Survival Analysis in Health Economics HTAi Bilbao 2012
 
Incidence or incidence rate (Epidemiology short lecture)
Incidence or incidence rate (Epidemiology short lecture)Incidence or incidence rate (Epidemiology short lecture)
Incidence or incidence rate (Epidemiology short lecture)Muhammad Akbar Rashid Qadri
 
Cross sectional studies
Cross sectional studiesCross sectional studies
Cross sectional studiessoudfaiza
 
Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Tarekk Alazabee
 
Randomization
Randomization Randomization
Randomization roshnijabi
 
Systematic review and meta analaysis course - part 1
Systematic review and meta analaysis course - part 1Systematic review and meta analaysis course - part 1
Systematic review and meta analaysis course - part 1Ahmed Negida
 
Confidence interval & probability statements
Confidence interval & probability statements Confidence interval & probability statements
Confidence interval & probability statements DrZahid Khan
 
1. Introduction to epidemiological study designs
1. Introduction to epidemiological study designs1. Introduction to epidemiological study designs
1. Introduction to epidemiological study designsRazif Shahril
 
Biostatistics exam questions by tadele girum
Biostatistics exam questions  by tadele girumBiostatistics exam questions  by tadele girum
Biostatistics exam questions by tadele girumTadele Girum
 
Epidemic Investigation.pdf
Epidemic Investigation.pdfEpidemic Investigation.pdf
Epidemic Investigation.pdfDinaOmer4
 
Calculating person time
Calculating person timeCalculating person time
Calculating person timeKadium
 

What's hot (20)

bio statistics for clinical research
bio statistics for clinical researchbio statistics for clinical research
bio statistics for clinical research
 
Question study design
Question study designQuestion study design
Question study design
 
Survival analysis
Survival  analysisSurvival  analysis
Survival analysis
 
Inferential statictis ready go
Inferential statictis ready goInferential statictis ready go
Inferential statictis ready go
 
Parametric Survival Analysis in Health Economics
Parametric Survival Analysis   in Health Economics Parametric Survival Analysis   in Health Economics
Parametric Survival Analysis in Health Economics
 
Incidence or incidence rate (Epidemiology short lecture)
Incidence or incidence rate (Epidemiology short lecture)Incidence or incidence rate (Epidemiology short lecture)
Incidence or incidence rate (Epidemiology short lecture)
 
Cross sectional studies
Cross sectional studiesCross sectional studies
Cross sectional studies
 
Odds ratios (Basic concepts)
Odds ratios (Basic concepts)Odds ratios (Basic concepts)
Odds ratios (Basic concepts)
 
Randomization
Randomization Randomization
Randomization
 
Systematic review and meta analaysis course - part 1
Systematic review and meta analaysis course - part 1Systematic review and meta analaysis course - part 1
Systematic review and meta analaysis course - part 1
 
INTRODUCTION TO BIO STATISTICS
INTRODUCTION TO BIO STATISTICS INTRODUCTION TO BIO STATISTICS
INTRODUCTION TO BIO STATISTICS
 
Confidence interval & probability statements
Confidence interval & probability statements Confidence interval & probability statements
Confidence interval & probability statements
 
1. Introduction to epidemiological study designs
1. Introduction to epidemiological study designs1. Introduction to epidemiological study designs
1. Introduction to epidemiological study designs
 
Biostatistics exam questions by tadele girum
Biostatistics exam questions  by tadele girumBiostatistics exam questions  by tadele girum
Biostatistics exam questions by tadele girum
 
Part 1 Survival Analysis
Part 1 Survival AnalysisPart 1 Survival Analysis
Part 1 Survival Analysis
 
BIOSTATISTICS
BIOSTATISTICSBIOSTATISTICS
BIOSTATISTICS
 
Introduction to meta analysis
Introduction to meta analysisIntroduction to meta analysis
Introduction to meta analysis
 
Epidemic Investigation.pdf
Epidemic Investigation.pdfEpidemic Investigation.pdf
Epidemic Investigation.pdf
 
Calculating person time
Calculating person timeCalculating person time
Calculating person time
 
Part 2 Cox Regression
Part 2 Cox RegressionPart 2 Cox Regression
Part 2 Cox Regression
 

Similar to Analysis and Interpretation

Statistics in meta analysis
Statistics in meta analysisStatistics in meta analysis
Statistics in meta analysisDr Shri Sangle
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011NES
 
Biostatistics clinical research & trials
Biostatistics clinical research & trialsBiostatistics clinical research & trials
Biostatistics clinical research & trialseclinicaltools
 
Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slidesBartsMSBlog
 
Baker esni handouts reading papers
Baker esni handouts reading papersBaker esni handouts reading papers
Baker esni handouts reading papersBartsMSBlog
 
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptIntroduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptAnnaMarieAndalRanill
 
Sample Size Estimation and Statistical Test Selection
Sample Size Estimation  and Statistical Test SelectionSample Size Estimation  and Statistical Test Selection
Sample Size Estimation and Statistical Test SelectionVaggelis Vergoulas
 
2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - FinalBrian Lin
 
Analytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational DataAnalytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational DataCTSI at UCSF
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Isla Kuhn
 
Importance of evidence
Importance of evidenceImportance of evidence
Importance of evidencesahughes
 
Research methods 2 operationalization &amp; measurement
Research methods 2   operationalization &amp; measurementResearch methods 2   operationalization &amp; measurement
Research methods 2 operationalization &amp; measurementattique1960
 
Quantitative_analysis.ppt
Quantitative_analysis.pptQuantitative_analysis.ppt
Quantitative_analysis.pptmousaderhem1
 
25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.ppt25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.pptPriyankaSharma89719
 

Similar to Analysis and Interpretation (20)

Statistics in meta analysis
Statistics in meta analysisStatistics in meta analysis
Statistics in meta analysis
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
 
Biostatistics clinical research & trials
Biostatistics clinical research & trialsBiostatistics clinical research & trials
Biostatistics clinical research & trials
 
Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slides
 
Baker esni handouts reading papers
Baker esni handouts reading papersBaker esni handouts reading papers
Baker esni handouts reading papers
 
Metaanalysis copy
Metaanalysis    copyMetaanalysis    copy
Metaanalysis copy
 
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptIntroduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
 
Sample Size Estimation and Statistical Test Selection
Sample Size Estimation  and Statistical Test SelectionSample Size Estimation  and Statistical Test Selection
Sample Size Estimation and Statistical Test Selection
 
Meta analysis with R
Meta analysis with RMeta analysis with R
Meta analysis with R
 
2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final
 
Analytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational DataAnalytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational Data
 
Bgy5901
Bgy5901Bgy5901
Bgy5901
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015
 
Displaying your results
Displaying your resultsDisplaying your results
Displaying your results
 
Bias and validity
Bias and validityBias and validity
Bias and validity
 
Importance of evidence
Importance of evidenceImportance of evidence
Importance of evidence
 
Research methods 2 operationalization &amp; measurement
Research methods 2   operationalization &amp; measurementResearch methods 2   operationalization &amp; measurement
Research methods 2 operationalization &amp; measurement
 
Quantitative_analysis.ppt
Quantitative_analysis.pptQuantitative_analysis.ppt
Quantitative_analysis.ppt
 
Session1b.ppt
Session1b.pptSession1b.ppt
Session1b.ppt
 
25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.ppt25_Anderson_Biostatistics_and_Epidemiology.ppt
25_Anderson_Biostatistics_and_Epidemiology.ppt
 

More from Francisco J Grajales III

Patient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharingPatient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharingFrancisco J Grajales III
 
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...Francisco J Grajales III
 
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare StudentsMulti-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare StudentsFrancisco J Grajales III
 
Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers Francisco J Grajales III
 
Las TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas alláLas TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas alláFrancisco J Grajales III
 
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...Francisco J Grajales III
 
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Francisco J Grajales III
 
E-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica BoatengE-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica BoatengFrancisco J Grajales III
 
eHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in AfricaeHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in AfricaFrancisco J Grajales III
 
ICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-HealthICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-HealthFrancisco J Grajales III
 
Electronic Health Records Global Perspectives
Electronic Health Records Global PerspectivesElectronic Health Records Global Perspectives
Electronic Health Records Global PerspectivesFrancisco J Grajales III
 
Interoperability Standards: The Key to Mobile Data
Interoperability Standards:The Key to Mobile DataInteroperability Standards:The Key to Mobile Data
Interoperability Standards: The Key to Mobile DataFrancisco J Grajales III
 
Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...Francisco J Grajales III
 
Role of standards, consumer education and media literacy
Role of standards, consumer education and media literacyRole of standards, consumer education and media literacy
Role of standards, consumer education and media literacyFrancisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Francisco J Grajales III
 

More from Francisco J Grajales III (20)

Patient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharingPatient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharing
 
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
 
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare StudentsMulti-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
 
Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers
 
Las TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas alláLas TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas allá
 
Panorama Internacional del eHealth
Panorama Internacional del eHealthPanorama Internacional del eHealth
Panorama Internacional del eHealth
 
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
 
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
 
Forumclinic Reshape 09
Forumclinic Reshape 09Forumclinic Reshape 09
Forumclinic Reshape 09
 
E-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica BoatengE-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica Boateng
 
eHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in AfricaeHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in Africa
 
ICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-HealthICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-Health
 
Electronic Health Records Global Perspectives
Electronic Health Records Global PerspectivesElectronic Health Records Global Perspectives
Electronic Health Records Global Perspectives
 
Interoperability Standards: The Key to Mobile Data
Interoperability Standards:The Key to Mobile DataInteroperability Standards:The Key to Mobile Data
Interoperability Standards: The Key to Mobile Data
 
Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...
 
Role of standards, consumer education and media literacy
Role of standards, consumer education and media literacyRole of standards, consumer education and media literacy
Role of standards, consumer education and media literacy
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 

Recently uploaded

What is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdfWhat is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdfMounikaPolabathina
 
Manual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditManual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditSkynet Technologies
 
Generative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfGenerative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfIngrid Airi González
 
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Mark Goldstein
 
Passkey Providers and Enabling Portability: FIDO Paris Seminar.pptx
Passkey Providers and Enabling Portability: FIDO Paris Seminar.pptxPasskey Providers and Enabling Portability: FIDO Paris Seminar.pptx
Passkey Providers and Enabling Portability: FIDO Paris Seminar.pptxLoriGlavin3
 
2024 April Patch Tuesday
2024 April Patch Tuesday2024 April Patch Tuesday
2024 April Patch TuesdayIvanti
 
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...panagenda
 
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality AssuranceInflectra
 
Potential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and InsightsPotential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and InsightsRavi Sanghani
 
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptxThe Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptxLoriGlavin3
 
From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .Alan Dix
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc
 
Assure Ecommerce and Retail Operations Uptime with ThousandEyes
Assure Ecommerce and Retail Operations Uptime with ThousandEyesAssure Ecommerce and Retail Operations Uptime with ThousandEyes
Assure Ecommerce and Retail Operations Uptime with ThousandEyesThousandEyes
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteDianaGray10
 
The Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and ConsThe Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and ConsPixlogix Infotech
 
Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...Farhan Tariq
 
Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...
Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...
Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...Alkin Tezuysal
 
The State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptxThe State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptxLoriGlavin3
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024Lonnie McRorey
 
A Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software DevelopersA Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software DevelopersNicole Novielli
 

Recently uploaded (20)

What is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdfWhat is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdf
 
Manual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditManual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance Audit
 
Generative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfGenerative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdf
 
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
 
Passkey Providers and Enabling Portability: FIDO Paris Seminar.pptx
Passkey Providers and Enabling Portability: FIDO Paris Seminar.pptxPasskey Providers and Enabling Portability: FIDO Paris Seminar.pptx
Passkey Providers and Enabling Portability: FIDO Paris Seminar.pptx
 
2024 April Patch Tuesday
2024 April Patch Tuesday2024 April Patch Tuesday
2024 April Patch Tuesday
 
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
 
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
 
Potential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and InsightsPotential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and Insights
 
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptxThe Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
The Role of FIDO in a Cyber Secure Netherlands: FIDO Paris Seminar.pptx
 
From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
 
Assure Ecommerce and Retail Operations Uptime with ThousandEyes
Assure Ecommerce and Retail Operations Uptime with ThousandEyesAssure Ecommerce and Retail Operations Uptime with ThousandEyes
Assure Ecommerce and Retail Operations Uptime with ThousandEyes
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test Suite
 
The Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and ConsThe Ultimate Guide to Choosing WordPress Pros and Cons
The Ultimate Guide to Choosing WordPress Pros and Cons
 
Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...Genislab builds better products and faster go-to-market with Lean project man...
Genislab builds better products and faster go-to-market with Lean project man...
 
Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...
Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...
Unleashing Real-time Insights with ClickHouse_ Navigating the Landscape in 20...
 
The State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptxThe State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptx
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024
 
A Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software DevelopersA Journey Into the Emotions of Software Developers
A Journey Into the Emotions of Software Developers
 

Analysis and Interpretation

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Risk ratio (RR) aka relative risk RR = a / (a+b) c / (c+d) Risk/ probability/ chance of the occurrence of an event in treatment relative to control Intervention Control a+b=n I c+d=n C Event No event d c b a
  • 8. Sample RR Calculation Death No death RR = 14/133 = 0.11 = 0.13 128/148 0.86 Drug 133 148 Placebo 20 128 119 14
  • 9. Odds ratio (OR) Intervention Control No event Event OR = a / b c / d Odds of an event occurring to it not occurring for treatment relative to control a+b=n I c+d=n C d c b a
  • 10. Sample OR Calculation Death No death Drug Placebo 133 148 OR = 14/119 = 0.12 = 0.019 128/20 6.4 20 128 119 14
  • 11. Interpreting (for intervention) Increased odds (harmful) Increased odds (beneficial) OR>1 (6.4/0.12) Reduced odds (beneficial) Reduced odds (not beneficial) OR<1 (0.12/6.4) No difference No difference OR=1, RR=1 Increased risk (harmful) Increased risk (beneficial) RR>1 (0.86/0.11) Reduced risk (beneficial) Reduced risk (not beneficial) RR<1 (0.11/0.86) Bad outcome (e.g. infection) Good outcome (e.g. remission)
  • 12.
  • 13. Closer Look at Odds RR = 0.11 / 0.86 = 0.13 ↑ A rate (11%) OR = 0.12 / 6.4 = 0.019 ↑ ~1:9 ↑ ~7:1
  • 14.
  • 15. Risk Difference (RD) Death No death Actual difference in risk of events Placebo Drug 133 148 RD = 14/133 – 128/148 = 0.11 – 0.86 = - 0.75 20 128 119 14
  • 16.
  • 17.
  • 18.
  • 19.
  • 21.
  • 22.
  • 23. Fixed Effects Analysis in Picture View
  • 24. Random Effects Analysis in Picture View
  • 25. Random effects in RevMan 5 ← DerSimonian and Laird random effects model
  • 26. Random effects in RevMan 5 (continued) ← DerSimonian and Laird random effects model
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36. I 2 Statistic (continued) * Importance of I 2 value depends on: ● magnitude and direction of effects ● strength of evidence of heterogeneity - Chi-squared P value, or - I 2 confidence interval Considerable heterogeneity* 75% to 100% May represent substantial heterogeneity* 50% to 90% May represent moderate heterogeneity* 30% to 60% Might not be important 0% to 40% Guide to Interpretation I 2 value
  • 37. Sample Forest Plot: Q and I 2
  • 38.
  • 39.
  • 40.
  • 42.